Sponsored Links
| CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Russia |
 |
 |
 |
| Medical News - Ear, Nose and Throat | |||
|
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia... Read more: Ear, Nose and Throat News From Medical News Today
|